Colorectal Cancer
Advertisement
The study’s primary end point was objective response rate determined through blinded independent central review.
Immunoscore also showed prognostic benefit in DNA mismatch repair proficient disease.
This approval marks the first tumor-agnostic approval of a HER2-directed therapy.
In patients with stage 4 colon cancer and unresectable metastases, PTR before chemotherapy was not related to increased OS.
Dr. Kasi showcases NEST-1, a look at adverse events and downstaging effects from neoadjuvant bot/bal in pMMR/MSS CRC.
Dr. Kasi breaks down BESPOKE CRC, a tumor-informed ctDNA assay to inform adjuvant chemo treatment decisions in stage 2/3 CRC.
Previous studies have demonstrated that patients with rectal cancer and enlarged LLNs experience a higher risk of LLR.
Recent studies have demonstrated the efficacy of blood-based and stool DNA tests as CRC screening options.
Dr. Christopher Lieu gives an overview of the BESPOKE trial and the GALAXY arm of CIRCULATE-Japan, as well as NETTER-2.
Dr. Pant discusses the relationship between T cell response magnitude and tumor biomarker reduction.
A2B530 is the first autologous logic-gated cell therapy developed using A2 Biopharmaceutical’s Tmod platform.
Dr. Eng discusses how fruquintinib differs from other VEGFR inhibitors.
The sNDA is based on results of KRYSTAL-1, which evaluated adagrasib alone or in combos for patients with KRAS G12C mutation.
The multitarget FIT has been found to exhibit a sensitivity for advanced neoplasia and advanced adenomas.
Individuals who test positive for H pylori may experience a higher rate of CRC incidence and mortality.
TNT with induction chemoimmunotherapy and long-course chemoradiation may lead to high CR in high-risk, pMMR rectal cancer.
Both CD8IE and FoxP3IS showed independent prognostic value as RFS markers in bivariable and multivariable analyses.
Nivolumab plus ipilimumab showed significant improvement in progression-free survival in patients in the first line setting.
The ELI-002 vaccine uses T cells to identify and remove tumor cells containing KRAS G12D- or G12R-mutated cancer.
GLP-1RAs are linked to a decreased risk of CRC compared with insulin and other antidiabetic drugs.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.